Search filters
Filters
Clear AllPhase
-
183
-
156
-
2
-
194
-
1
-
152
-
17
-
402
Age
-
1246
-
593
Gender
-
29
-
49
-
3
-
1172
Virtual Trials
-
1247
-
6
New Trials
-
4
-
1249
Found 1253 All Conditions trials
A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
UPCC 07718: INSPIRE: A Multicenter Randomized Controlled Trial integrating health informatics in a scalable
We would like to rely on the Fred Hutchinson Cancer Research Center (FHCRC) as IRB of record for this study. We are doing this study to examine ways to improve the health of long-term survivors of bone marrow or blood stem cell transplant. We want to know if an online …
UPCC 10122 A Randomized Open-label Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1
The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) and pembrolizumab versus treatment of physician's choice (TPC) and pembrolizumab in participants with previously untreated, locally advanced inoperable or metastatic triple-negative breast cancer, whose tumors express programmed cell death ligand 1 (PD-L1).
UPCC 06918:A Phase 1a/1b Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Solid Tumors
We are requesting to rely on WIRB as IRB of record for this study. This Study has 2 parts. The purpose of the Part 1 is to try to find the best dose of INCB081776 alone for patients who have advanced cancer. The purpose of Part 2 is to find …
UPCC 04223: Brightline-2: A Phase IIa/IIb open-label single-arm multi-centre trial of BI 907828 for treatment of patients with locally advanced / metastatic MDM2 amplified TP53 wild-type biliary tract adenocarcinoma pancreatic ductal adenocarcinoma or other selected solid tumours
This study is open to adults with advanced cancer in the biliary tract, pancreas, lung, or bladder for whom previous treatment was not successful or no treatment exists, to find out whether a medicine called BI 907828 helps. BI 907828 is a so-called MDM2 inhibitor that is being developed to …
Evaluating Using Rescue Therapies for CAR T cell Related Cytokine Release Syndrome (CRS) and HLH-like Syndrome
This research study is being conducted to evaluate experimental rescue therapies for the treatment of cytokine release syndrome (CRS) and CAR T cell related HLH-like syndrome (CRHLS). These are both life-threatening side effects which can occur in some patients after infusion with a CAR T cell product. This consent allows …
Study of Direct Brain Recording and Stimulation for Memory Enhancement (Data Coordinating Center Protocol) (PRIME)
The purpose of this research study is to learn more about how the brain stores and retrieves different kinds of information from memory, and whether brain stimulation can improve the storage and retrieval of memories. We are enrolling subjects with drug-resistant epilepsy, who are expected to undergo placement of electrodes …
Study to Evaluate Study Drug XmAb 20717 in Subjects with Selected Advanced Solid Tumors (DUET-2)
The primary purposes of this research study are to determine the safety and tolerability of dose levels of the investigational drug, XmAb20717, and if XmAb20717 works in treating advanced solid tumors that have progressed after treatment with standard cancer therapies or solid tumors for which there are no appropriate therapies …
NRG-GY026: A Phase II/III Study of Paclitaxel/Carboplatin Alone or Combined With Either Trastuzumab and Hyaluronidase-oysk (HERCEPTIN HYLECTA) or Pertuzumab Trastuzumab and Hyaluronidase-zzxf (PHESGO) in HER2 Positive Stage I-IV Endometrial Serous Carcinoma or Carcinosarcoma
This Study tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin HylectaTM) or pertuzumab, trastuzumab and hyaluronidase-zzxf (PhesgoTM) to the usual chemotherapy (paclitaxel and carboplatin) works to shrink tumors in patients with HER2 positive endometrial serous carcinoma or carcinosarcoma. We would like to rely on CIRB as the IRB of record for …
UPCC 03423: A Phase 1b/2a Open-label Study to Evaluate the Safety Tolerability Pharmacokinetics and Pharmacodynamics of DISC-0974 in Participants with Myelofibrosis and Anemia
This phase 1b/2a open-label study will assess the safety, tolerability, pharmacokinetics and pharmacodynamics of DISC-0974 as well as categorize the effects on anemia response in subjects with myelofibrosis and anemia. We would like to rely on Advarra as the IRB of record for this study.
UPCC 16122 A Phase II Multicentre Open-Label Study to Assess the Efficacy and Safety of Olaparib Monotherapy and Olaparib Plus Durvalumab Combination as Neoadjuvant Therapy in Patients with BRCA Mutations and Early Stage HER2-Negative Breast Cancer (OlympiaN)
This study to learn more about olaparib and olaparib plus durvalumab combination therapy and also to better understand the studied disease, breast cancer, and associated health problems.
Please choose between Voice or SMS based delivery of verification code
or